Lymphoma, B Cell Clinical Trial
Official title:
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma.
This is a single-centre, randomised, open label Phase I clinical trial of CD19 Chimeric Antigen Receptor (CAR) T-cells (CD19 CAR T-cells) in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma. Following informed consent and registration to the trial, Patients will receive the allogeneic CD19 CAR T-cells following lymphodepleting chemotherapy. The study will evaluate the safety, efficacy and duration of response of the CD19 CAR T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00210379 -
Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Terminated |
NCT00523939 -
DepoCyt for Active Lymphomatous or Leukemic Meningitis
|
Phase 2 | |
| Completed |
NCT02679196 -
The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
|
Phase 1 | |
| Completed |
NCT00210314 -
Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Withdrawn |
NCT00210340 -
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
|
Phase 1 |